A research study to explore the impact of GP support via text messages to patients with asthma and/or chronic obstructive pulmonary disease

A randomised controlled trial to evaluate the impact of supportive text messages from GP practices on self-reported symptoms and inhaler adherence in patients with asthma and/or chronic obstructive pulmonary disease who have been prescribed a preventer (daily) inhaler

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10376144

Enrollment

4000

Registered

2022-08-09

Start date

2023-03-06

Completion date

Unknown

Last updated

2023-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, chronic obstructive pulmonary disease (COPD) Respiratory Asthma, Other chronic obstructive pulmonary disease

Interventions

This trial will be a 6-month prospective, randomised controlled trial in which the study population is randomly allocated (1:1) to an intervention or control group. The trial is multicentre and is non

some will contain information about how to use a preventer inhaler, some will emphasise the importance of using it, and some will provide simple reminders to patients to take their inhaler.

the text message intervention with be in addition to their usual care.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide informed consent and comply with the study instructions 2. Male and females age 18 years or older 3. Confirmed diagnosis of asthma and/or COPD as recorded in the patient’s GP medical record 4. Currently prescribed a preventer inhaler 5. Access to a mobile phone 6. Ability to check text messages on phone 7. Ability to read

Exclusion criteria

Exclusion criteria: 1. Inability to understand the study procedures 2. Inability or reluctance to provide responses to the study questionnaires 3. Inability to receive and respond to text messages

Design outcomes

Primary

Measure	Time frame
Medication adherence measured using the MARS-5 Questionnaire from baseline (week 1) to midpoint (week 13) and endpoint (week 26)	—

Secondary

Measure	Time frame
1. Symptom control measured using the Asthma Control Test from baseline (week 1) to midpoint (week 13) and endpoint (week 26). (for asthma patients) 2. Symptom control measured using the COPD Assessment Test from baseline (week 1) to midpoint (week 13) and endpoint (week 26) (for COPD patients and patients with both asthma and COPD) 3. Days between consecutive preventer inhaler prescription requests measured using medical record data from baseline (week 1) to midpoint (week 13) and endpoint (week 26) 4. Differences in the number of emergency admissions between the intervention and control groups measured using bespoke survey questions over the 26-week trial period 5. Differences in the utilisation of NHS resources between the intervention and control groups measured using bespoke survey questions over the 26-week trial period	—

Measure

Time frame

1. Symptom control measured using the Asthma Control Test from baseline (week 1) to midpoint (week 13) and endpoint (week 26). (for asthma patients) 2. Symptom control measured using the COPD Assessment Test from baseline (week 1) to midpoint (week 13) and endpoint (week 26) (for COPD patients and patients with both asthma and COPD) 3. Days between consecutive preventer inhaler prescription requests measured using medical record data from baseline (week 1) to midpoint (week 13) and endpoint (week 26) 4. Differences in the number of emergency admissions between the intervention and control groups measured using bespoke survey questions over the 26-week trial period 5. Differences in the utilisation of NHS resources between the intervention and control groups measured using bespoke survey questions over the 26-week trial period

—

Countries

England, United Kingdom

Contacts

Public ContactVictoria Fussey

tori@accurx.com+44 (0)7597001378

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026